Indian pharma firms likely to see muted revenue growth from US generics market in FY23: Icra https://ift.tt/EbuUoRS

On the outlook, Icra vice president and co-group head Kinjal Shah said, "Icra expects mid to high single-digit price erosion to continue to exert pressure over the near term, resulting in muted revenue growth for the Indian pharmaceutical companies from the US generics market in FY23."

from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/HBLmuoX